Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Inventory: 2013-2018

Historic Change in Inventory for Theravance Biopharma (TBPH) over the last 6 years, with Dec 2018 value amounting to $1.1 million.

  • Theravance Biopharma's Change in Inventory fell 75.17% to $1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.6 million, marking a year-over-year decrease of 77.69%. This contributed to the annual value of $1.6 million for FY2018, which is 77.69% down from last year.
  • Theravance Biopharma's Change in Inventory amounted to $1.1 million in Q4 2018, which was up 435.82% from $201,000 recorded in Q3 2018.
  • Over the past 5 years, Theravance Biopharma's Change in Inventory peaked at $4.3 million during Q4 2017, and registered a low of -$912,000 during Q4 2015.
  • In the last 3 years, Theravance Biopharma's Change in Inventory had a median value of $504,000 in 2017 and averaged $1.0 million.
  • As far as peak fluctuations go, Theravance Biopharma's Change in Inventory soared by 7,096.15% in 2014, and later tumbled by 542.72% in 2015.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Change in Inventory stood at $206,000 in 2014, then crashed by 542.72% to -$912,000 in 2015, then spiked by 247.37% to $1.3 million in 2016, then spiked by 222.77% to $4.3 million in 2017, then plummeted by 75.17% to $1.1 million in 2018.
  • Its Change in Inventory was $1.1 million in Q4 2018, compared to $201,000 in Q3 2018 and -$20,000 in Q2 2018.